ARX 201

Drug Profile

ARX 201

Alternative Names: ARX-201; PEG-hGH

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ambrx
  • Class Growth hormones; Hormonal replacements; Polyethylene glycols
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Somatotropin deficiency

Most Recent Events

  • 16 Jul 2013 Biomarkers information updated
  • 21 May 2013 ARX 201 is in phase II development for Somatotropin deficiency
  • 17 Nov 2008 Final safety and efficacy data from a phase I/II trial in Somatotropin deficiency released by Ambrx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top